The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 601–700 of 1,027
Krychtiuk, K. A., Ahrens, I., Drexel, H., Halvorsen, S., Hassager, C., Huber, K., Kurpas, D., Niessner, A., Schiele, F., Semb, A. G., et al. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac123 · Cited by 100
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., Sedlis, S. P., Kostuk, W. J., Spertus, J. A., Dada, M. R., CHAITMAN, B. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.051 · Cited by 100
Shah, S. J., Waters, D. D., Barter, P. J., Kastelein, J. J. P., Shepherd, J., WENGER, N. K., DeMicco, D. A., Breazna, A., & LaRosa, J. C. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.054 · Cited by 100
Hou, R., & Goldberg, A. C. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.007 · Cited by 100
Lipinski, M. J., Cauthen, C. A., Biondi‐Zoccai, G., Abbate, A., Vrtovec, B., Khan, B. V., & Vetrovec, G. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.055 · Cited by 100
Identification of Genetic Variants Associated With Response to Statin Therapy
Mega, J. L., Morrow, D. A., Brown, A. H., Cannon, C. P., & Sabatine, M. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.188474 · Cited by 100
Self-citationShepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
Statin‐associated myopathy and its exacerbation with exercise
Meador, B. M., & Huey, K. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21817 · Cited by 99
Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 99
Colchicine’s Role in Cardiovascular Disease Management
Buckley, L. F., & Libby, P. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319851 · Cited by 99
Cardiac MRI of ischemic heart disease at 3T: Potential and challenges
Wieben, O. E., François, C. J., & Reeder, S. B. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.10.022 · Cited by 99
Medical Treatment of Peripheral Arterial Disease: A Comprehensive Review
Stoyioglou, A., & Jaff, M. R. (2004) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000137978.15352.c6 · Cited by 99
Rahimi, K., Bhala, N. B., Kamphuisen, P. W., Emberson, J., Biere‐Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. J. V. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 99
Goldschmidt‐Clermont, P. J., Creager, M. A., Lorsordo, D. W., Lam, G. K. W., Wassef, M. K., & Dzau, V. J. (2005) · Circulation · doi:10.1161/circulationaha.105.577460 · Cited by 99
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 98
The Effects of Medications on Myocardial Perfusion
Zoghbi, G. J., Dorfman, T. A., & Iskandrian, A. E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.035 · Cited by 98
Howard, W. J. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70060-x · Cited by 98
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.008 · Cited by 98
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M. A., Murphy, S. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.586347 · Cited by 97
Self-citationBlazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
Self-citationCirculating transcriptome reveals markers of atherosclerosis
Patino, W. D., Mian, O. Y., Kang, J., Matoba, S., Bartlett, L. D., Holbrook, B. M., Trout, H. H., Kozloff, L., & Hwang, P. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408032102 · Cited by 96
Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy
Hirayama, A., Saito, S., Ueda, Y., Takayama, T., Honye, J., Komatsu, S., Yamaguchi, O., Li, Y., Yajima, J., Nanto, S., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0755 · Cited by 96
Impact of Intensive LDL Cholesterol Lowering on Coronary Artery Atherosclerosis Progression
Shin, S., Park, H., Chang, H., Arsanjani, R., Min, J. K., Kim, Y.-J., Lee, B. K., Choi, J.-H., Hong, G., & Chung, N. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.04.013 · Cited by 96
Ginsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Li, Y., Liu, Y., Fu, L., Mei, C., & Dai, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034450 · Cited by 95
Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk
Lin, I., Sung, J., Sanchez, R. J., Mallya, U. G., Friedman, M., Panaccio, M. P., Koren, A., Neumann, P. J., & Menzin, J. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.685 · Cited by 95
Role of Niacin in Current Clinical Practice: A Systematic Review
Garg, A., Sharma, A., Krishnamoorthy, P. M., Garg, J., Virmani, D., Sharma, T., Stefanini, G. G., Kostis, J. B., Mukherjee, D., & Sikorskaya, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.038 · Cited by 95
Bempedoic Acid: for Whom and When
Ruscica, M., Sirtori, C. R., Carugo, S., Banach, M., & Corsini, A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01054-2 · Cited by 95
C-Reactive Protein Increase in Unstable Coronary Disease
Servi, S. D., Mariani, M., Mariani, G., & Mazzone, A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.083 · Cited by 95
Hiro, T., Kimura, T., Morimoto, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, K., Saito, S., Yamaguchi, T., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0766 · Cited by 94
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Navar, A. M., Wang, T. Y., Li, S., Robinson, J. G., Goldberg, A. C., Virani, S., Roger, V. L., Wilson, P. W. F., Elassal, J., Lee, L. V., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.005 · Cited by 94
LDL Cholesterol: The Lower the Better
Martin, S. S., Blumenthal, R. S., & Miller, M. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.009 · Cited by 94
Watanabe, K., Sugiyama, S., Kugiyama, K., Honda, O., Fukushima, H., Koga, H., Horibata, Y., Hirai, T., Sakamoto, T., Yoshimura, M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.070 · Cited by 94
Baylis, R. A., Gomez, D. A., Mallat, Z., Pasterkamp, G., & Owens, G. K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310097 · Cited by 94
Metabolic syndrome and endothelial dysfunction
Fornoni, A., & Raij, L. R. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0080-6 · Cited by 93
Intravascular Ultrasound for the Evaluation of Therapies Targeting Coronary Atherosclerosis
Böse, D., von Birgelen, C., & Erbel, R. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.067 · Cited by 93
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Link, A., Ayadhi, T., Böhm, M., & Nickenig, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl277 · Cited by 93
Strey, C. H., Young, J. M., Molyneux, S. L., George, P. M., Florkowski, C. M., Scott, R. S., & FRAMPTON, C. M. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.009 · Cited by 93
Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers
Hayward, R. A., Kent, D. M., Vijan, S. S., & Hofer, T. P. (2005) · Health Affairs · doi:10.1377/hlthaff.24.6.1571 · Cited by 93
Cellular and molecular mechanisms of statins: an update on pleiotropic effects
Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., & Nakamura, M. (2015) · Clinical Science · doi:10.1042/cs20150027 · Cited by 92
Schiele, F., Aktaa, S., Rosselló, X., Ahrens, I., Claeys, M. J., Collet, J., Fox, K. A. A., Gale, C. P., Huber, K., Iakobishvili, Z., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaa037 · Cited by 92
Bonnet, J., McPherson, R., Tedgui, A., Simoneau, D., Nozza, A., Martineau, P., & Davignon, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.023 · Cited by 92
Rodríguez-Granillo, G. A., Fadden, E. P. M., Valgimigli, M., van Mieghem, C. A. G., Regar, E. S., de Feyter, P. J., & Serruys, P. W. J. C. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.040 · Cited by 92
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Virani, S. S. (2011) · Europe PMC (PubMed Central) · Cited by 91
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms
Liberale, L., Carbone, F., Montecucco, F., & Sahebkar, A. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105735 · Cited by 91
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 91
Guglielmi, V., Bellia, A., Pecchioli, S., Della‐Morte, D., Parretti, D., Cricelli, I., Medea, G., Sbraccia, P., Lauro, D., Cricelli, C. A., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.05.018 · Cited by 91
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
Gencer, B., Mach, F., Murphy, S. A., Ferrari, G. M. D., Huber, K., Lewis, B. S., Ferreira, J., Kurtz, C. E., Wang, H., Honarpour, N., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0882 · Cited by 90
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 90
Self-citationSettergren, M., Böhm, F., Rydén, L., & Pernow, J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn166 · Cited by 90
Couvert, P., Giral, P., Dejager, S., Gu, J. Z., Huby, T., Chapman, M. J., Bruckert, É., & Carrié, A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1217 · Cited by 90
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-20 · Cited by 90
Atherosclerotic risk factor control in patients with peripheral arterial disease
Rehring, T. F., Sandhoff, B. G., Stolcpart, R. S., Merenich, J. A., & Hollis, H. W. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.01.047 · Cited by 90
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Mayer, G., & Poirier, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 89
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., & Ben, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054268 · Cited by 89
Anderson, J. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.015 · Cited by 89
Frcp, C. G., & de Silva, J. (2013) · Cited by 89
Nosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.105 · Cited by 88
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 88
Liu, H., Cao, Y., Jin, J., Zhang, H., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Xu, R., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014581 · Cited by 88
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman, R., Merdler, I., Case, B. C., Waksman, O., & Porto, I. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00606 · Cited by 88
CHENG, A. Y. Y., & Leiter, L. A. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231412.15049.fb · Cited by 88
Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 88
Practical use of the Framingham risk score in primary prevention: Canadian perspective.
Bosomworth, N. J. (2011) · Europe PMC (PubMed Central) · Cited by 88
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients
Bruckert, É., Baccara‐Dinet, M. T., McCoy, F., & Chapman, J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74871 · Cited by 88
Hou, J., Xing, L., Jia, H., Vergallo, R., Soeda, T., Minami, Y., Hu, S., Yang, S., Zhang, S., Lee, H., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.062 · Cited by 87
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 87
Rahman, M. S., & Woollard, K. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57613-8_7 · Cited by 87
Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome
Wang, T. Y., Newby, L. K., Chen, A. Y., Mulgund, J., Roe, M. T., Sonel, A. F., Bhatt, D. L., DeLong, E. R., Ohman, E. M., Gibler, W. B., et al. (2009) · Clinical Cardiology · doi:10.1002/clc.20518 · Cited by 87
Mulhall, J. P., Telöken, P., Brock, G. B., & Kim, E. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00286.x · Cited by 87
Anselmino, M., Malmberg, K., Öhrvik, J., Rydén, L., & and on behalf of the Euro Heart Survey Investigators (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f335d0 · Cited by 87
Relation of Fractional Flow Reserve After Drug-Eluting Stent Implantation to One-Year Outcomes
Nam, C., Hur, S., Cho, Y., Park, H., Yoon, H., Kim, H., Chung, I., Kim, Y.-N., Kim, K., Doh, J., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.329 · Cited by 87
Kohli, P., Wallentin, L. C., Reyes, E., Horrow, J. C., Husted, S., Angiolillo, D. J., Ardissino, D., Maurer, G., Morais, J., Nicolau, J. C., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.124248 · Cited by 87
Self-citationGanse, E. H. V., Laforest, L., Alemao, E., Davies, G., Gutkin, S. W., & Yin, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59139 · Cited by 87
Wolfram, R. M., Brewer, H. B., Xue, Z., Satler, L. F., Pichard, A. D., Kent, K. M., & Waksman, R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.006 · Cited by 86
In vivo siRNA delivery with dendritic poly( l -lysine) for the treatment of hypercholesterolemia
Watanabe, K., Harada‐Shiba, M., Suzuki, A., Gokuden, R., Kurihara, R., Sugao, Y., Mori, T., Katayama, Y., & Niidome, T. (2009) · Molecular BioSystems · doi:10.1039/b900880b · Cited by 86
Toi, T., Taguchi, I., Yoneda, S., Kageyama, M., Kikuchi, A., Tokura, M., Kanaya, T., Abe, S., Matsuda, R., & Kaneko, N. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1051 · Cited by 86
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 86
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 86
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 86
Factors underlying regression of coronary atheroma with potent statin therapy
Puri, R., Nissen, S. E., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., John, J. S., Wolski, K., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht084 · Cited by 86
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513000200 · Cited by 86
NITRIC OXIDE-DEPENDENT ENDOTHELIAL FUNCTION AND CARDIOVASCULAR DISEASE
Desjardins, F., & Balligand, J. (2006) · Acta Clinica Belgica · doi:10.1179/acb.2006.052 · Cited by 86
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 86
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 86
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 86
Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome
Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., II, & Newby, L. K. (2015) · Circulation · doi:10.1161/cir.0000000000000183 · Cited by 85
Nozue, T., Yamamoto, S., Tohyama, S., Umezawa, S., Kunishima, T., Sato, A., Miyake, S., Takeyama, Y., Morino, Y., Yamauchi, T., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.004 · Cited by 84
Brož, P., Ben-Haim, N., Grzelakowski, M., Marsch, S. C. U., Meier, W. P., & Hunziker, P. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181624aed · Cited by 84
Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014
Rosenson, R. S., Farkouh, M. E., Mefford, M. T., Bittner, V., Brown, T. M., Taylor, B., Monda, K. L., Zhao, H., Dai, Y., & Muntner, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.585 · Cited by 84
Safety of High-Dose Atorvastatin Therapy
Waters, D. D. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.028 · Cited by 84
Prevalence and risk factors of muscle complications secondary to statins
El‐Salem, K., Ababneh, B., Rudnicki, S., Malkawi, A., Alrefai, A., Khader, Y., Saadeh, R., & Saydam, M. (2011) · Muscle & Nerve · doi:10.1002/mus.22205 · Cited by 83
Vrablik, M., Seifert, B., Parkhomenko, A., Banach, M., Jóźwiak, J. J., Kiss, R. G., Gaita, D., Rašlová, K., Zachlederova, M., Bray, S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.035 · Cited by 83
Clinical Implications of Pharmacogenetic Variation on the Effects of Statins
Maggo, S. D. S., Kennedy, M. A., & Clark, D. W. J. (2010) · Drug Safety · doi:10.2165/11584380-000000000-00000 · Cited by 83
Yang, X. H., Zhang, B. L., Cheng, Y., Fu, S. K., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.012 · Cited by 83
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
